AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
A personalised rehabilitation programme for adults with multiple long-term conditions is both acceptable and deliverable, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback